secwatch / observer
8-K filed March 6, 2026, 6:59 PM ET ticker ALLR CIK 0001860657
debt confidence high sentiment neutral materiality 0.60

Allarity Therapeutics, Inc. (ALLR): debt financing — Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes

Allarity Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Allarity Therapeutics, Inc. incurred loan of $10,930,000 (A-1 Note) and $10,000,000 (B Note) with Streeterville Capital, LLC at 9.00% per annum and 5.00% per annum maturing 18 months following the date of issuance.

Instrument
loan
Principal
$10,930,000 (A-1 Note) and $10,000,000 (B Note)
Counterparty
Streeterville Capital, LLC
Rate
9.00% per annum and 5.00% per annum
Maturity
18 months following the date of issuance
Event
incurrence
Exact text from the filing
On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Allarity Therapeutics, Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000) (effective 2026-03-02).

Action
entry
Agreement
credit facility
Counterparty
Streeterville Capital, LLC
Value
$20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000)
Effective
2026-03-02
Exact text from the filing
On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).
View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-26-024339
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.